Quick Takeaways
- Bellevue Group AG filed SCHEDULE 13G for Celldex Therapeutics, Inc. Common Stock (CLDX).
- Disclosed ownership: 5.4%.
- Date of event: 18 Aug 2025.
Bellevue Group AG - 18 Aug 2025 SCHEDULE 13G Report for Celldex Therapeutics, Inc. Common Stock (CLDX)
- Filing Manager
- Bellevue Group AG
- Reporting Manager
- Bellevue Group AG
- Symbol
- CLDX
- Shares outstanding
- 66,993,870 shares
- Disclosed Ownership
- 3,617,669 shares
- Ownership
- 5.4%
- Form type
- SCHEDULE 13G
- Filing time
- 14 Nov 2025, 19:58:46 UTC
- Date of event
- 18 Aug 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Bellevue Group AG disclosed 5.4% ownership in Celldex Therapeutics, Inc. Common Stock (CLDX) on 18 Aug 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Nov 2025, 19:58.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Bellevue Group AG | 5.4% | 3,617,669 | 0 | 3,617,669 | /s/ Stefano Montalbano | Stefano Montalbano/ Chief Financial Officer | |
| Bellevue Asset Management AG | 5.4% | 3,617,669 | 0 | 3,617,669 | /s/ Christoph Eisenring | Christoph Eisenring/ Head Legal & Compliance |